 blood-based metabolic signature alzheimer 's disease introduction identification blood-based metabolic change might provide early easy-to-obtain biomarkers method include ad patient control csf-biomarker-confirmed diagnosis cut-off tau beta mass spectrometry platform determine concentration amine organic acid lipid oxidative stress compound multiple signature assess differential expression nest linear model classification logistic regression regulatory network extraction result twenty-six metabolite differentially express metabolite improve classification performance clinical variable network model identify hub metabolic dysregulation tyrosine glycylglycine glutamine lysophosphatic acid c platelet activate factor c metabolite network apoe epsilon negative ad patient less cohesive compare network apoe epsilon positive ad patient discussion multiple signature point various promising peripheral marker validation network difference ad patient accord apoe genotype may reflect different pathway ad